The initial public offering (IPO) of Sai Parenteral Limited has grabbed headlines as it entered Day 2 of bidding on March 25, 2026, with investors watching closely. The ₹409 crore issue opened on March 24 with a price band of ₹372–₹392 per share. Early subscription figures have been underwhelming, and the grey market premium (GMP) remains flat at ₹0, hinting that the stock could list around its IPO price.
This muted start has sparked debate among market watchers and retail investors alike. What’s driving the slow demand? And what might it mean for listing gains and long‑term value? Keep reading to understand the latest subscription trends, investor sentiment, and what experts are saying about this pharmaceutical IPO’s prospects.
Sai Parenteral IPO Day 2 Demand & GMP Trends
How has the subscription trended so far?
The Sai Parenteral IPO, which opened on March 24, 2026, has seen a slow start in demand. On Day 1, subscription was weak with only around 0.05 × the issue getting subscribed by end of Day 1, reflecting muted investor interest across categories.
On Day 2 (March 25, 2026), subscription remained low, reaching just about 4 % of the total issue by midday, signaling limited momentum in bidding. The IPO bidding window closes on March 27, 2026, after which the basis of allotment is expected to be finalised on March 30.
What does the grey market premium (GMP) suggest?
The grey market premium (GMP) for Sai Parenteral’s IPO has been flat at ₹0, indicating that unofficial market sentiment suggests a neutral to flat listing around the issue price. This trend has held steady since the IPO opened.
Investors often watch GMP to gauge early sentiment, but it is unofficial and should not be the sole basis for decisions. Analysts note that flat GMP generally points to conservative investor expectations.
What is the price band and issue size?
The IPO price band is set at ₹372-₹392 per share, with a minimum lot size of 38 shares (~₹14,896). The total issue size is approximately ₹409 crore. The issue comprises a fresh equity component of ₹285 crore and an Offer for Sale (OFS) of about ₹124 crore.
What are key timelines for allotment and listing?
Here are the important dates investors should note:
- Last day of subscription: March 27, 2026
- Allotment finalisation: March 30, 2026
- Refund initiation: April 1, 2026
- Shares credited to demat: April 1, 2026
- Listing on BSE and NSE: April 2, 2026
What do analysts say about the IPO?
Brokerages have mixed views on Sai Parenteral’s IPO. Some like SBI Securities and Ashika Institutional Equities recommend subscribing for long‑term investment, citing the company’s operational footprint. Others such as Swastika Investmart have rated it avoid, pointing to valuation and demand concerns.
Investors are advised to look beyond GMP and consider fundamentals like business model, financials, and growth strategy before making subscription decisions.
Sai Parenteral IPO Company & Business Profile
What does Sai Parenteral Limited do?
Sai Parenteral’s Limited is a diversified pharmaceutical formulations company with a portfolio spanning branded generic medicines and Contract Development & Manufacturing Organization (CDMO) services.
The company operates multiple manufacturing facilities in India and has a presence in markets such as Australia, New Zealand, Southeast Asia and the Middle East. It specialises in injectables, tablets, capsules and other dosage forms.
What are the use of IPO proceeds?
According to prospectus details, net proceeds from the IPO are earmarked for:
- Capacity expansion and upgradation of manufacturing facilities
- Establishment of a new R&D centre
- Working capital requirements
- Repayment of certain borrowings
- General corporate purposes
These objectives aim to strengthen the company’s production and research capabilities in a competitive global pharma market.
Risk & Investment Considerations for Sai IPO
What are key risks?
Investors should consider the following risk factors before applying:
- Manufacturing operations are largely centred in specific regions, exposing the business to regional risks.
- Profitability and revenue growth have been moderate in recent years.
- The IPO includes an OFS component, meaning existing shareholders are selling part of their holdings.
Is this Sai Parenteral IPO suitable for long‑term investors?
Analysts bullish on the issue believe the company’s global footprint, accreditation of facilities, and CDMO focus could support longer‑term growth. However, given the slow subscription pace and neutral GMP, short‑term listing gains are currently uncertain.
A balanced approach, weighing fundamentals against IPO demand trends and macro conditions, is essential. Some investors may use an AI stock analysis tool to cross‑check valuation signals and company metrics before deciding.
Conclusion
Sai Parenteral’s IPO has generated muted demand by Day 2, with subscription still low and GMP holding at ₹0, suggesting a neutral listing outlook. While the company’s operations and growth plans have appeal, cautious investor interest so far underscores the need for careful evaluation.
Prospective investors should consider both long‑term business fundamentals and market sentiment indicators before choosing to subscribe, especially given mixed broker views and evolving primary market trends.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)